Anti-Tumor Immunity Elicited by Peptide Complex-Alpha-Fetoprotein and Glycoprotein 96
Purposes: To construct a recombinant vaccine alpha-fetoprotein (AFP)-glycoprotein (gp96) complex, and study its ability to induce specific CTL response and its protective effect against AFP-producing tumor. Material/Methods: A recombinant vaccine was constructed by conjugating mouse alpha-fetoprotei...
Gespeichert in:
| Veröffentlicht in: | Applied Mechanics and Materials 2012-01, Vol.195-196, p.397-401 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 401 |
|---|---|
| container_issue | |
| container_start_page | 397 |
| container_title | Applied Mechanics and Materials |
| container_volume | 195-196 |
| creator | Wang, Xiao Ping Wang, Qiao Xia Lin, Huan Ping |
| description | Purposes: To construct a recombinant vaccine alpha-fetoprotein (AFP)-glycoprotein (gp96) complex, and study its ability to induce specific CTL response and its protective effect against AFP-producing tumor. Material/Methods: A recombinant vaccine was constructed by conjugating mouse alpha-fetoprotein to glycoprotein 96. By way of intracutaneous injection, mice were primed and boosted with recombinant vaccine mAFP/gp96, whereas single mAFP or gp96 injection as controls. The ELISPOT and ELISA were used to measure the frequency of cells producing the cytokine IFN-gama in splenocytes and the level of anti-AFP antibody of serum from immunized mice respectively. In vivo tumor challenge was carried out to assess the immune effect of the recombinant vaccine. Results: By recombinant mAFP/gp96 vaccine immunization, the results of ELISPOT and ELISA showed that the number of splenic cells producing IFN-gama and the level of anti-AFP antibody of serum were significantly higher in mAFP/gp96 group than those in mAFP and gp96 groups (122.50±9.30 IFN-gama spots/106 cells vs 46.40±10.32 IFN-gama spots/106 cells, 12.14±7.33 IFN-gama spots/106 cells, P |
| doi_str_mv | 10.4028/www.scientific.net/AMM.195-196.397 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1442911839</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3102703881</sourcerecordid><originalsourceid>FETCH-LOGICAL-c340t-fe2c807be4915513eda6ebd1f867e8ff0fd816d6dc78c70ac32df5674dd01d423</originalsourceid><addsrcrecordid>eNqNkMtKAzEUhoMXUKvvMOBOyDSZZDLJstZbwaKLug7T5ART5uZMSp23N1pRly4OB875-X74ELqiJOUkk9PdbpcOxkMTvPMmbSBMZ8tlSlWOqRIpU8UBOqVCZLjgMjtEZ4ywQuZcKHb09SBYMSZO0NkwbAgRnHJ5il5mkYdX27rtk0VdbxsfxuS28sYHsMl6TJ6hC95CMm_rroJ3PKu61xLfQWi7vg3gm6RsbHJfjebnoMQ5OnZlNcDF956gl7vb1fwBPz7dL-azR2wYJwE7yIwkxRq4onlOGdhSwNpSJ0UB0jnirKTCCmsKaQpSGpZZl4uCW0uo5RmboMs9N1a_bWEIetNu-yZWasp5piiVTMXU9T5l-nYYenC6631d9qOmRH-61dGt_nWro1sd3eroNo7Q0W2E3OwhoS-bIYB5_dP1f8wHfzGLaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1442911839</pqid></control><display><type>article</type><title>Anti-Tumor Immunity Elicited by Peptide Complex-Alpha-Fetoprotein and Glycoprotein 96</title><source>Scientific.net Journals</source><creator>Wang, Xiao Ping ; Wang, Qiao Xia ; Lin, Huan Ping</creator><creatorcontrib>Wang, Xiao Ping ; Wang, Qiao Xia ; Lin, Huan Ping</creatorcontrib><description>Purposes: To construct a recombinant vaccine alpha-fetoprotein (AFP)-glycoprotein (gp96) complex, and study its ability to induce specific CTL response and its protective effect against AFP-producing tumor. Material/Methods: A recombinant vaccine was constructed by conjugating mouse alpha-fetoprotein to glycoprotein 96. By way of intracutaneous injection, mice were primed and boosted with recombinant vaccine mAFP/gp96, whereas single mAFP or gp96 injection as controls. The ELISPOT and ELISA were used to measure the frequency of cells producing the cytokine IFN-gama in splenocytes and the level of anti-AFP antibody of serum from immunized mice respectively. In vivo tumor challenge was carried out to assess the immune effect of the recombinant vaccine. Results: By recombinant mAFP/gp96 vaccine immunization, the results of ELISPOT and ELISA showed that the number of splenic cells producing IFN-gama and the level of anti-AFP antibody of serum were significantly higher in mAFP/gp96 group than those in mAFP and gp96 groups (122.50±9.30 IFN-gama spots/106 cells vs 46.40±10.32 IFN-gama spots/106 cells, 12.14±7.33 IFN-gama spots/106 cells, P<0.01; 164.52±11.22 µg/mL vs 56.32±8.23 µg/mL, 7.56±3.47 µg/mL, P< 0.01). The tumor volume in mAFP/gp96 group was significantly smaller than that in mAFP and gp96 groups (32.46±6.35 mm3 vs 384.16±11.43 mm3, 832.54±12.72 mm3, P< 0.01). Conclusions: The study further confirmed the function of glycoprotein 96s immune adjuvant. Sequential immunization with recombinant mAFP/gp96 vaccine could generate effective antitumor immunity on AFP-producing tumor. The recombined mAFP/gp96 vaccine may be suitable for serving as an immunotherapy for hepatocellular carcinoma.</description><identifier>ISSN: 1660-9336</identifier><identifier>ISSN: 1662-7482</identifier><identifier>ISBN: 3037854693</identifier><identifier>ISBN: 9783037854693</identifier><identifier>EISSN: 1662-7482</identifier><identifier>DOI: 10.4028/www.scientific.net/AMM.195-196.397</identifier><language>eng</language><publisher>Zurich: Trans Tech Publications Ltd</publisher><ispartof>Applied Mechanics and Materials, 2012-01, Vol.195-196, p.397-401</ispartof><rights>2012 Trans Tech Publications Ltd</rights><rights>Copyright Trans Tech Publications Ltd. Aug 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c340t-fe2c807be4915513eda6ebd1f867e8ff0fd816d6dc78c70ac32df5674dd01d423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttps://www.scientific.net/Image/TitleCover/1935?width=600</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Wang, Xiao Ping</creatorcontrib><creatorcontrib>Wang, Qiao Xia</creatorcontrib><creatorcontrib>Lin, Huan Ping</creatorcontrib><title>Anti-Tumor Immunity Elicited by Peptide Complex-Alpha-Fetoprotein and Glycoprotein 96</title><title>Applied Mechanics and Materials</title><description>Purposes: To construct a recombinant vaccine alpha-fetoprotein (AFP)-glycoprotein (gp96) complex, and study its ability to induce specific CTL response and its protective effect against AFP-producing tumor. Material/Methods: A recombinant vaccine was constructed by conjugating mouse alpha-fetoprotein to glycoprotein 96. By way of intracutaneous injection, mice were primed and boosted with recombinant vaccine mAFP/gp96, whereas single mAFP or gp96 injection as controls. The ELISPOT and ELISA were used to measure the frequency of cells producing the cytokine IFN-gama in splenocytes and the level of anti-AFP antibody of serum from immunized mice respectively. In vivo tumor challenge was carried out to assess the immune effect of the recombinant vaccine. Results: By recombinant mAFP/gp96 vaccine immunization, the results of ELISPOT and ELISA showed that the number of splenic cells producing IFN-gama and the level of anti-AFP antibody of serum were significantly higher in mAFP/gp96 group than those in mAFP and gp96 groups (122.50±9.30 IFN-gama spots/106 cells vs 46.40±10.32 IFN-gama spots/106 cells, 12.14±7.33 IFN-gama spots/106 cells, P<0.01; 164.52±11.22 µg/mL vs 56.32±8.23 µg/mL, 7.56±3.47 µg/mL, P< 0.01). The tumor volume in mAFP/gp96 group was significantly smaller than that in mAFP and gp96 groups (32.46±6.35 mm3 vs 384.16±11.43 mm3, 832.54±12.72 mm3, P< 0.01). Conclusions: The study further confirmed the function of glycoprotein 96s immune adjuvant. Sequential immunization with recombinant mAFP/gp96 vaccine could generate effective antitumor immunity on AFP-producing tumor. The recombined mAFP/gp96 vaccine may be suitable for serving as an immunotherapy for hepatocellular carcinoma.</description><issn>1660-9336</issn><issn>1662-7482</issn><issn>1662-7482</issn><isbn>3037854693</isbn><isbn>9783037854693</isbn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNqNkMtKAzEUhoMXUKvvMOBOyDSZZDLJstZbwaKLug7T5ART5uZMSp23N1pRly4OB875-X74ELqiJOUkk9PdbpcOxkMTvPMmbSBMZ8tlSlWOqRIpU8UBOqVCZLjgMjtEZ4ywQuZcKHb09SBYMSZO0NkwbAgRnHJ5il5mkYdX27rtk0VdbxsfxuS28sYHsMl6TJ6hC95CMm_rroJ3PKu61xLfQWi7vg3gm6RsbHJfjebnoMQ5OnZlNcDF956gl7vb1fwBPz7dL-azR2wYJwE7yIwkxRq4onlOGdhSwNpSJ0UB0jnirKTCCmsKaQpSGpZZl4uCW0uo5RmboMs9N1a_bWEIetNu-yZWasp5piiVTMXU9T5l-nYYenC6631d9qOmRH-61dGt_nWro1sd3eroNo7Q0W2E3OwhoS-bIYB5_dP1f8wHfzGLaQ</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>Wang, Xiao Ping</creator><creator>Wang, Qiao Xia</creator><creator>Lin, Huan Ping</creator><general>Trans Tech Publications Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7SR</scope><scope>7TB</scope><scope>8BQ</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BFMQW</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>HCIFZ</scope><scope>JG9</scope><scope>KB.</scope><scope>KR7</scope><scope>L6V</scope><scope>M7S</scope><scope>PDBOC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope></search><sort><creationdate>20120101</creationdate><title>Anti-Tumor Immunity Elicited by Peptide Complex-Alpha-Fetoprotein and Glycoprotein 96</title><author>Wang, Xiao Ping ; Wang, Qiao Xia ; Lin, Huan Ping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c340t-fe2c807be4915513eda6ebd1f867e8ff0fd816d6dc78c70ac32df5674dd01d423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Xiao Ping</creatorcontrib><creatorcontrib>Wang, Qiao Xia</creatorcontrib><creatorcontrib>Lin, Huan Ping</creatorcontrib><collection>CrossRef</collection><collection>Engineered Materials Abstracts</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Continental Europe Database</collection><collection>Technology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>SciTech Premium Collection</collection><collection>Materials Research Database</collection><collection>Materials Science Database</collection><collection>Civil Engineering Abstracts</collection><collection>ProQuest Engineering Collection</collection><collection>Engineering Database</collection><collection>Materials Science Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><jtitle>Applied Mechanics and Materials</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Xiao Ping</au><au>Wang, Qiao Xia</au><au>Lin, Huan Ping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-Tumor Immunity Elicited by Peptide Complex-Alpha-Fetoprotein and Glycoprotein 96</atitle><jtitle>Applied Mechanics and Materials</jtitle><date>2012-01-01</date><risdate>2012</risdate><volume>195-196</volume><spage>397</spage><epage>401</epage><pages>397-401</pages><issn>1660-9336</issn><issn>1662-7482</issn><eissn>1662-7482</eissn><isbn>3037854693</isbn><isbn>9783037854693</isbn><abstract>Purposes: To construct a recombinant vaccine alpha-fetoprotein (AFP)-glycoprotein (gp96) complex, and study its ability to induce specific CTL response and its protective effect against AFP-producing tumor. Material/Methods: A recombinant vaccine was constructed by conjugating mouse alpha-fetoprotein to glycoprotein 96. By way of intracutaneous injection, mice were primed and boosted with recombinant vaccine mAFP/gp96, whereas single mAFP or gp96 injection as controls. The ELISPOT and ELISA were used to measure the frequency of cells producing the cytokine IFN-gama in splenocytes and the level of anti-AFP antibody of serum from immunized mice respectively. In vivo tumor challenge was carried out to assess the immune effect of the recombinant vaccine. Results: By recombinant mAFP/gp96 vaccine immunization, the results of ELISPOT and ELISA showed that the number of splenic cells producing IFN-gama and the level of anti-AFP antibody of serum were significantly higher in mAFP/gp96 group than those in mAFP and gp96 groups (122.50±9.30 IFN-gama spots/106 cells vs 46.40±10.32 IFN-gama spots/106 cells, 12.14±7.33 IFN-gama spots/106 cells, P<0.01; 164.52±11.22 µg/mL vs 56.32±8.23 µg/mL, 7.56±3.47 µg/mL, P< 0.01). The tumor volume in mAFP/gp96 group was significantly smaller than that in mAFP and gp96 groups (32.46±6.35 mm3 vs 384.16±11.43 mm3, 832.54±12.72 mm3, P< 0.01). Conclusions: The study further confirmed the function of glycoprotein 96s immune adjuvant. Sequential immunization with recombinant mAFP/gp96 vaccine could generate effective antitumor immunity on AFP-producing tumor. The recombined mAFP/gp96 vaccine may be suitable for serving as an immunotherapy for hepatocellular carcinoma.</abstract><cop>Zurich</cop><pub>Trans Tech Publications Ltd</pub><doi>10.4028/www.scientific.net/AMM.195-196.397</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1660-9336 |
| ispartof | Applied Mechanics and Materials, 2012-01, Vol.195-196, p.397-401 |
| issn | 1660-9336 1662-7482 1662-7482 |
| language | eng |
| recordid | cdi_proquest_journals_1442911839 |
| source | Scientific.net Journals |
| title | Anti-Tumor Immunity Elicited by Peptide Complex-Alpha-Fetoprotein and Glycoprotein 96 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T16%3A54%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-Tumor%20Immunity%20Elicited%20by%20Peptide%20Complex-Alpha-Fetoprotein%20and%20Glycoprotein%2096&rft.jtitle=Applied%20Mechanics%20and%20Materials&rft.au=Wang,%20Xiao%20Ping&rft.date=2012-01-01&rft.volume=195-196&rft.spage=397&rft.epage=401&rft.pages=397-401&rft.issn=1660-9336&rft.eissn=1662-7482&rft.isbn=3037854693&rft.isbn_list=9783037854693&rft_id=info:doi/10.4028/www.scientific.net/AMM.195-196.397&rft_dat=%3Cproquest_cross%3E3102703881%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1442911839&rft_id=info:pmid/&rfr_iscdi=true |